EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility

Michael B MacIsaac iD, Bradley Whitton, Adrian Hubble, Shelley Cogger, Matthew Penn, Anthony Weeks, Kasey Elmore, David Pemberton, Jenine Anderson, Rebecca Howard, Una McKeever, Timothy Papaluca und 8 weitere

Medical Journal of Australia · 03.04.2023 · 218 (6) · 256-261

DOI: 10.5694/mja2.51885 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Journal of Australia, online erschienen am 14.03.2023. Verfasst von Michael B MacIsaac und 19 weiteren Autor:innen. Beteiligte Einrichtung: St Vincent's Hospital Melbourne, Melbourne, VIC. Hauptthemen laut MEDLINE: Drug Users, Hepatitis C, Chronic, Substance Abuse, Intravenous, Hepatitis C. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the feasibility of testing and treating people who inject drugs at a supervised injecting facility for hepatitis C virus (HCV) infection.

Design

Retrospective cohort study. Setting, participants People who inject drugs who attended the Melbourne supervised injecting facility, 30 June 2018 – 30 June 2020. Main outcome measures Proportion of people tested for hepatitis C; proportions of people positive for anti‐HCV antibody and HCV RNA, and of eligible people prescribed direct‐acting antiviral (DAA) treatment; sustained virological response twelve weeks or more after treatment completion.

Results

Of 4649 people who attended the supervised injecting facility during 2018–20, 321 were tested for hepatitis C (7%); 279 were anti‐HCV antibody‐positive (87%), of whom 143 (51%) were also HCV RNA‐positive. Sixty‐four of 321 had previously been treated for hepatitis C (20%), 21 had clinically identified cirrhosis (7%), eight had hepatitis B infections (2%), and four had human immunodeficiency virus infections (1%). In multivariate analyses, people tested for hepatitis C were more likely than untested clients to report psychiatric illness (adjusted odds ratio [aOR], 9.65; 95% confidence interval [CI], 7.26–12.8), not have a fixed address (aOR, 1.59; 95% CI, 1.18–2.14), and to report significant alcohol use (aOR, 1.57; 95% CI, 1.06–2.32). The median number of injecting facility visits was larger for those tested for hepatitis C (101; interquartile range [IQR], 31–236) than for those not tested (20; IQR, 3–90). DAA treatment was prescribed for 126 of 143 HCV RNA‐positive clients (88%); 41 of 54 with complete follow‐up data were cured (76%).

Conclusions

People who attend supervised injecting facilities can be tested and treated for hepatitis C on site. Models that provide streamlined, convenient hepatitis C care promote engagement with treatment in a group in which the prevalence of hepatitis C is high.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug UsersHepatitis C, ChronicSubstance Abuse, IntravenousHepatitis CHumansAntiviral AgentsHepacivirusNeedle-Exchange ProgramsRetrospective StudiesAustraliaRNA

Stichwörter der Autor:innen

Hepatitis CHepatitis, viralPolicy, drugs and alcoholWorld Health Organization

Substanzen

Antiviral AgentsRNA

Autor:innen und Institutionen

  • St Vincent's Hospital Melbourne, Melbourne, VIC.
  • The University of Melbourne, Melbourne, VIC.
  • North Richmond Community Health, Melbourne, VIC.
  • The Burnet Institute, Melbourne, VIC.
  • Monash University, Melbourne, VIC.
  • Alfred Health, Melbourne, VIC.

ORCID-Profile: Michael B MacIsaac, Margaret E Hellard

Zitieren

APA

MacIsaac, M. B., Whitton, B., Hubble, A., Cogger, S., Penn, M., Weeks, A., Elmore, K., Pemberton, D., Anderson, J., Howard, R., McKeever, U., Papaluca, T., Hellard, M. E., Stoove, M., Wilson, D., Pedrana, A., Doyle, J., Clark, N., Holmes, J., & Thompson, A. J. (2023). Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility. Medical Journal of Australia, 218(6), 256-261. https://doi.org/10.5694/mja2.51885

Vancouver

MacIsaac MB, Whitton B, Hubble A, Cogger S, Penn M, Weeks A, et al. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility. Medical Journal of Australia. 2023;218(6):256-261. doi:10.5694/mja2.51885

BibTeX
@article{MacIsaac2023,
  author = {MacIsaac, Michael B and Whitton, Bradley and Hubble, Adrian and Cogger, Shelley and Penn, Matthew and Weeks, Anthony and Elmore, Kasey and Pemberton, David and Anderson, Jenine and Howard, Rebecca and McKeever, Una and Papaluca, Timothy and Hellard, Margaret E and Stoove, Mark and Wilson, David and Pedrana, Alisa and Doyle, Joseph and Clark, Nico and Holmes, Jacinta and Thompson, Alexander J},
  title = {Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility},
  journal = {Medical Journal of Australia},
  year = {2023},
  volume = {218},
  number = {6},
  pages = {256--261},
  doi = {10.5694/mja2.51885}
}
Kostenlos starten →